Dana Thompson, MD
Medical Oncology · Nashville, TNNPI 1306862669
Payments from drug & device makers
Across 483 payments — averaging $702.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$230K
- Rigel Pharmaceuticals, Inc.$107K
- Adaptive Biotechnologies Corporation$391
- Novartis$300
- Merck$284
- AstraZeneca$244
- plus $1K from 24 others
Across 1 payment — averaging $4696.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Consulting fees$67,53620%
- Speaking & faculty fees$206,00761%
- Travel & lodging$57,66417%
- Food & beverage$8,2372%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 273 | $229,988 |
| Rigel Pharmaceuticals, Inc. | 117 | $107,026 |
| Adaptive Biotechnologies Corporation | 3 | $391 |
| Novartis | 15 | $300 |
| Merck | 13 | $284 |
| AstraZeneca(2 entities) | 7 | $244 |
| Daiichi Sankyo Inc. | 6 | $228 |
| Gilead(2 entities) | 2 | $159 |
| Astellas Pharma US Inc | 7 | $112 |
| E.r. Squibb & Sons, L.L.C. | 6 | $111 |
| Bayer | 5 | $91 |
| Bristol Myers Squibb | 3 | $65 |
| CTI Biopharma Corp. | 3 | $49 |
| AbbVie | 2 | $48 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $47 |
| Eisai Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Pfizer | 2 | $35 |
| Partner Therapeutics, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $24 |
| Springworks Therapeutics, Inc. | 1 | $22 |
| Deciphera Pharmaceuticals Inc. | 1 | $21 |
| Puma Biotechnology, Inc. | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$339,489 in reported general payments places this provider in the 70th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 132 | $2,370,803 |
| JakafiRuxolitinib Phosphate | 42 | $713,373 |
| PomalystPomalidomide | 32 | $708,343 |
| ImbruvicaIbrutinib | 35 | $537,424 |
| VenclextaVenetoclax | 40 | $451,981 |
| XtandiEnzalutamide | 34 | $448,001 |
| CalquenceAcalabrutinib Maleate | 30 | $418,087 |
| ErleadaApalutamide | 24 | $335,691 |
| TukysaTucatinib | 12 | $313,708 |
| LynparzaOlaparib | 18 | $292,254 |
| NubeqaDarolutamide | 25 | $228,763 |
| IbrancePalbociclib | 15 | $212,022 |
| BrukinsaZanubrutinib | 12 | $159,380 |
| TavalisseFostamatinib Disodium | 11 | $151,171 |
| TasignaNilotinib Hcl | 12 | $113,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $65 | $2,370,803132 claims |
| AstraZenecaCalquence, Lynparza | $244 | $710,34148 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $111 | $708,34332 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $47 | $537,42435 claims |
| AbbVieVenclexta | $48 | $451,98140 claims |
| Astellas Pharma US IncXtandi | $112 | $448,00134 claims |
| Johnson & JohnsonErleada, Xarelto | $24 | $346,62235 claims |
| BayerNubeqa | $91 | $228,76325 claims |
| PfizerIbrance | $35 | $212,02215 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $107,026 | $151,17111 claims |
| NovartisTasigna | $300 | $113,29112 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $15 | $1,942154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Nashville
- Melissa JohnsonNashville$46M
- David SpigelNashville$29.7M
- Howard BurrisNashville$12.2M
- Ingrid MayerNashville$6.3M
- Jennifer ChoeNashville$4.1M
- Cathy EngNashville$3.8M
- Jordan BerlinNashville$3.7M
- Kristen CiomborNashville$3.2M
- Vandana AbramsonNashville$3M
- Leora HornNashville$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.